OCSAW — Oculis Holding AG
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1953530 ·
Last close
$16.43
Market Cap
—
52W High
$16.43
52W Low
$16.43
ADV30
0
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -21,728,000 | -28,852,000 | 243,993,000 | 64,564,000 | 47,345,000 |
| Dec 2025 | 0 | — | -20,633,000 | -23,514,000 | 235,963,000 | 81,329,000 | 39,893,000 |
| Sep 2025 | 0 | — | -20,296,000 | -16,855,000 | 167,836,000 | 46,440,000 | 37,242,000 |
| Jun 2025 | 0 | — | -20,768,000 | -25,375,000 | 181,621,000 | 64,265,000 | 38,525,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-66,304,000
Investing CF
$-60,934,000
Financing CF
$186,918,000
CapEx
$-1,388,000
Dividends Paid
$0
Buybacks
—
EPS Diluted TTM
—
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-384,514,000
Inventory
—
Receivables
$1,794,000
ST Investments
$131,684,000
EBIT TTM
$-98,310,000
Pretax Income TTM
$-99,143,000
Interest Exp TTM
$833,000
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -81,672,000 | -98,957,000 | 235,963,000 | 39,893,000 | — | -66,304,000 |
| Dec 2024 | 0 | -73,204,000 | -85,777,000 | 120,353,000 | 46,970,000 | — | -48,919,000 |
| Dec 2023 | 0 | -45,851,000 | -88,802,000 | 114,353,000 | 20,625,000 | — | -55,037,000 |
| Dec 2022 | 0 | -32,376,000 | -38,698,000 | 37,060,000 | 135,051,000 | — | -25,074,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.02T | $1148.84 | — |
| JNJ | JOHNSON & JOHNSON | $617.78B | $256.35 | — |
| ABBV | AbbVie Inc. | $443.36B | $250.94 | — |
| MRK | Merck & Co., Inc. | $321.57B | $130.20 | — |
| NVSEF | NOVARTIS AG | $301.30B | $158.52 | — |
News headlines (Yahoo Finance, 1h cache)
Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference
2026-07-02 08:00 · Yahoo
Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026
2026-06-11 08:00 · Yahoo
Oculis Announces First Patient Randomized in PREDICT-1 Registrational Trial of Licaminlimab, Advancing Precision Medicine in Dry Eye Disease
2026-06-09 08:00 · Yahoo
Oculis to Present at the 47th Annual Goldman Sachs Global Healthcare Conference
2026-06-08 19:25 · Yahoo
Nan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug Stumbles
2026-06-08 11:16 · Yahoo
OCS Stock Drops Over 23% — Eye Drop Trial For Diabetic Vision Loss Misses Target
2026-05-29 20:18 · Yahoo
Oculis Holding AG Phase 3 Trial of Potential Eye Drops for Diabetic Patients Fails to Primary Endpoint
2026-05-29 19:46 · Yahoo
Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular Edema
2026-05-29 19:06 · Yahoo
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
2026-05-15 20:05 · Yahoo
Oculis Publishes Results of 2026 Annual General Meeting and Announces Election of Gregory D. Perry to its Board of Directors
2026-05-14 20:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.